Rhabdoid Tumors Cellular Architecture by Single-cell Analyses (InnovRT-2)

Launched by ASSISTANCE PUBLIQUE - HÔPITAUX DE PARIS · Jul 31, 2021

Keywords

ClinConnect Summary

The InnovRT-2 clinical trial is studying a type of childhood cancer called rhabdoid tumors, specifically focusing on how these tumors are made up of different types of cells. Researchers want to understand the variety within these tumors and how this diversity can affect how well treatments work. This information could help doctors find better ways to treat patients with rhabdoid tumors in the future.

To be eligible for this trial, participants must be between 0 and 17 years old and have a diagnosis of a rhabdoid tumor based on medical tests and imaging. They should have undergone surgery as part of their standard care and have enough tissue samples available for the study. Parents or guardians must agree to their child's participation. If eligible, participants can expect to provide tissue samples for research that may lead to a better understanding of this rare cancer and how to improve treatment options. The trial is currently recruiting participants, and it welcomes children of all genders.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Aged 0-17 years old
• • having a rhabdoid tumor according to clinical and radiological features Or likely having a rhabdoid tumor according to clinical and radiological features
• • surgical resection in standard care
• • sufficient material for both diagnosis and experimental procedures
• • parents' agreement